⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 2, 2010Nuclear Medicine Communications

The evolving role of PET/CT in breast cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Groheux, David; Giacchetti, Sylvie; Rubello, Domenico; Al-Nahhas, Adil; Moretti, Jean-luc; Espié, Marc; Hindié, Elif Author Information

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Groheux et al. (2010) studied this question.

synapsesocial.com/papers/6a74770ffd85dc9184090c51 https://doi.org/10.1097/mnm.0b013e3283354cb4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study GroupCohort Study · 2004 · 345 citations
2Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for <i>In vivo</i> ImagingIn Vitro Study · 2005 · 154 citations
3Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and <sup>18</sup>F-FluoroestradiolDiagnostic Study · 2008 · 249 citations
4Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parametersDiagnostic Study · 2007 · 252 citations
5Standardized Uptake Values for Breast Carcinomas Assessed by Fluorodeoxyglucose-Positron Emission Tomography Correlate with Prognostic FactorsCohort Study · 2007 · 64 citations